Get the Stockscreener App
46.95
0.32%
0.15
After Hours:
46.86
-0.09
-0.19%
Exact Sciences Corp stock is traded at $46.95, with a volume of 4.29M.
It is up +0.32% in the last 24 hours and down -11.65% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$46.80
Open:
$46.31
24h Volume:
4.29M
Relative Volume:
1.51
Market Cap:
$8.86B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-8.5209
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
-3.73%
1M Performance:
-11.65%
6M Performance:
-16.24%
1Y Performance:
+2.78%
1-Day Range:
$46.06
$49.57
1-Week Range:
$46.06
$49.57
52-Week Range:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
46.95 | 8.83B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Will Exact Sciences Corporation (EXAS) Continue to Penetrate the Market with Its Cologuard Test? - Yahoo.co
Exact Sciences, Humana partner to offer Cologuard Plus in-network By Investing.com - Investing.com Nigeria
Exact Sciences expands Humana partnership for colorectal cancer screening - StreetInsider
Major Medicare Coverage Win: Humana Adds Exact Sciences New Cancer Test for 5.8 Million Members - Stock Titan
Exact Sciences Corporation Recovery Gathers Momentum on Chart SignalsOptimized Watchlist With Daily Adjustments Launched - metal.it
What catalysts could drive Exact Sciences Corporation stock higher in 2025Breakout Stocks Tips For Beginners - jammulinksnews.com
How strong is Exact Sciences Corporation company’s balance sheetUnlock powerful stock screening tools - jammulinksnews.com
Exact Sciences Corporation Stock (EXAS) Opinions on Blood-Based Screening Developments - Quiver Quantitative
Lobbying Update: $480,000 of EXACT SCIENCES lobbying was just disclosed - Quiver Quantitative
Exact Sciences’ Oncodetect MRD Test Gains Medicare Coverage for Colorectal Cancer - Insider Monkey
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now? - Yahoo Finance
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Yahoo.co
3 Reasons EXAS is Risky and 1 Stock to Buy Instead - Yahoo Finance
BlackRock, Inc. Reduces Stake in Exact Sciences Corp by 32.30% - GuruFocus
Exact Sciences Corporation Stock Analysis and ForecastFree Stock Market Return Analysis - jammulinksnews.com
Palmetto wary of Prelude’s, Exact Sciences’ test for DCIS - BioWorld MedTech
U.S. Biomarkers Market Projected to Surpass USD 106.03 Billion by 2034 | CAGR: 15.6% - industrytoday.co.uk
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
What analysts say about Exact Sciences Corporation stockExplosive wealth accumulation - PrintWeekIndia
What drives Exact Sciences Corporation stock priceBreakthrough investment results - PrintWeekIndia
How to Invest in Financial Technology Stocks Strategic Stock Investment PlanFree Trend-Following Techniques - jammulinksnews.com
Is Exact Sciences Corporation a good long term investmentAccelerated earnings growth - jammulinksnews.com
Top Stocks for Wealth Management AI Powered Stock Selection StrategyHigh-performance investment picks - jammulinksnews.com
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know - Yahoo Finance
Canaccord Genuity reiterates Buy rating on Exact Sciences stock ahead of study - Investing.com
Envestnet Asset Management Inc. Buys 13,004 Shares of Freshpet, Inc. (NASDAQ:FRPT) - Defense World
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet - Yahoo Finance
Exact Sciences to release Q2 2025 results on August 6 By Investing.com - Investing.com Canada
Exact Sciences to release Q2 2025 results on August 6 - Investing.com Australia
Press Release: Exact Sciences Schedules Second Quarter 2025 Earnings Call - 富途牛牛
Exact Sciences Schedules Second Quarter 2025 Earnings Call - The Globe and Mail
EXAS SEC FilingsExact Sciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Exact Sciences stock rises as Canaccord maintains Buy rating By Investing.com - Investing.com Canada
Exact’s Cancer-Screening Patent Invalidated in Geneoscopy Win - Bloomberg Law News
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences’ ’781 Patent - Business Wire
August 29th Options Now Available For EXACT Sciences Corp. (EXAS) - Nasdaq
Exact Sciences stock rises as Canaccord maintains Buy rating - Investing.com
PTAB hands Exact a loss in Geneoscopy patent dispute - BioWorld MedTech
Exact Sciences’ Oncodetect test receives Medicare coverage By Investing.com - Investing.com Nigeria
Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage - MarketScreener
Exact Sciences’ Oncodetect test receives Medicare coverage - Investing.com Australia
Exact Sciences announces Medicare coverage for Oncodetect(TM) molecular residual disease - MarketScreener
Exact Sciences gains Medicare coverage for colorectal cancer test - StreetInsider
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer - Business Wire
What Makes Exact Sciences (EXAS) a New Buy Stock - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance
Tom Still: Cancer tests continue to propel Exact Sciences - ehextra.com
Concerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting Growth - MSN
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA) - Yahoo Finance
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):